S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

• C. Hasselbalch Riley,
• M. Hutchings,
• S.-S. Yoon,
• Y. Koh,
• S. Manier,
• T. Facon,
• S. J. Harrison,
• J. Er,
• F. Volzone,
• A. Pinto,
• C. Montes,
• E. M. Ocio,
• A. Alfonso-Pierola,
• P. Rodriguez Otero,
• F. Offner,
• A. Guidetti,
• P. Corradini,
• C. Titouan,
• C. Hulin,
• C. Touzeau,
• P. Moreau,
• R. Popat,
• S. Leong,
• R. Mazza,
• A.-M. E. Bröske,
• I. Dekhtiarenko,
• H.-J. Helms,
• S. Belli,
• T. Vardar,
• T. Fauti,
• J. Eckmann,
• T. Moore,
• M. Schneider,
• W. Jacob,
• M. Weisser,
• C. Carlo-Stella

Affiliations

C. Hasselbalch Riley

1 Rigshospitalet, Copenhagen, Denmark

M. Hutchings

1 Rigshospitalet, Copenhagen, Denmark

S.-S. Yoon

2 Seoul National University College of Medicine, Seoul, South Korea

Y. Koh

2 Seoul National University College of Medicine, Seoul, South Korea

S. Manier

3 Lille University Hospital, Lille, France

T. Facon

3 Lille University Hospital, Lille, France

S. J. Harrison

4 Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

J. Er

4 Peter MacCallum Cancer Center and Royal Melbourne Hospital, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

F. Volzone

5 Istituto Nazionale dei Tumori, Fondazione Pascale, IRCCS, Napoli, Italy

A. Pinto

5 Istituto Nazionale dei Tumori, Fondazione Pascale, IRCCS, Napoli, Italy

C. Montes

6 Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander

E. M. Ocio

6 Hospital Universitario Marques de Valdecilla (IDIVAL), Universidad de Cantabria, Santander

A. Alfonso-Pierola

7 Clinica Universidad de Navarra, Navarra, Spain

P. Rodriguez Otero

7 Clinica Universidad de Navarra, Navarra, Spain

F. Offner

8 Universitair Ziekenhuis Gent, Gent, Belgium

A. Guidetti

9 Istituto Nazionale dei Tumori, Milano, Italy

P. Corradini

9 Istituto Nazionale dei Tumori, Milano, Italy

C. Titouan

10 CHU de Bordeaux, Bordeaux

C. Hulin

10 CHU de Bordeaux, Bordeaux

C. Touzeau

11 CHU de Nantes, Nantes, France

P. Moreau

11 CHU de Nantes, Nantes, France

R. Popat

12 University College London Hospitals NHS Foundation Trust, London, United Kingdom

S. Leong

12 University College London Hospitals NHS Foundation Trust, London, United Kingdom

R. Mazza

13 Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy

A.-M. E. Bröske

14 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

I. Dekhtiarenko

15 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich

H.-J. Helms

16 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

S. Belli

16 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

T. Vardar

16 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

T. Fauti

15 Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich

J. Eckmann

14 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

T. Moore

14 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

M. Schneider

16 Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

W. Jacob

14 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

M. Weisser

14 Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany

C. Carlo-Stella

13 Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy